

1 **Letter**

2 **Impact of COVID-19 pandemic on tuberculosis care in India**

3 Aliabbas.A. Husain <sup>1</sup>, Tanya M. Monaghan<sup>2,3</sup>, Rajpal Singh Kashyap <sup>1#</sup>

4

5 <sup>1</sup>Research Centre, Dr G.M. Taori Central India Institute of Medical Sciences (CIIMS), Nagpur  
6 (Maharashtra), India

7 <sup>2</sup>NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust  
8 and the University of Nottingham, Nottingham, UK.

9 <sup>3</sup>Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham,  
10 Nottingham, UK.

11

12

13

14

15 **#Correspondence**

16 Rajpal Singh Kashyap

17 Research Centre,

18 Dr. G. M Taori Central India Institute of Medical Sciences,

19 88/2, Bajaj Nagar, Nagpur, India.

20 **E-mail:** [raj\\_ciims@rediffmail.com](mailto:raj_ciims@rediffmail.com)

21 **Telephone:** +91-712-2233381/2236441

22 **Fax:** 0712-2236416

23

24

25 **To the Editor,**

26

27 We reflect on the current and anticipated future impact of the COVID-19 pandemic on  
28 tuberculosis (TB) control in India. According to the latest figures from the WHO, India  
29 accounts for a quarter of all global & multidrug-resistant (MDR) TB cases [1]. Many cases  
30 remain undiagnosed, or when diagnosed are not treated, or appropriately notified. As a result,  
31 only 58% of overall estimated new and relapsing TB cases are notified in India, [1]. Despite  
32 concerted efforts driven mainly by the UN's Sustainable Development Goals, WHO End TB  
33 Strategy and the Government of India's National Strategic Plan (NSP) to eliminate TB by  
34 2025, the incidence of TB has been declining slowly. We have previously reported a high  
35 prevalence of latent TB in the Nagpurian population [2]. Risk factors such as poverty, low  
36 socioeconomic status, malnutrition with impaired immunity, poor housing, and inadequate  
37 ventilation were significantly associated with developing latent TB, and active case conversion.  
38 Since the nationwide lockdown commenced on March 25<sup>th</sup>, the number of COVID-19 cases in  
39 India has continued to surge. The number of confirmed cases of SARS-CoV-2 infection rose  
40 to 566,840 with 16,893 deaths as of June 30<sup>th</sup>, making it the country with the fourth highest  
41 number of reported cases. [3]

42 Due to current shifts in economic, and political priorities towards COVID-19 containment, it  
43 is our contention that national efforts to tackle TB are likely to be adversely affected. In terms  
44 of economic impact, an estimated 140 million Indian people have already lost their jobs during  
45 the current crisis. Lost earnings have been particularly harmful to the most marginalized, and  
46 impoverished communities, bolstering poverty, and malnutrition further, both of which are  
47 major risk factors that predispose to TB in rural and urban communities. As India continues to  
48 battle the coronavirus pandemic, the current lockdown is already leading to debilitating effects  
49 on TB services with limited access to health care, anti-tuberculous drugs, and disruption of

50 treatment services. The Stop TB partnership modelling analysis has assessed the potential  
51 effects of lockdown on TB incidence and mortality over the next 5 years in high burden  
52 settings. In the case of India, lockdown has resulted in a striking 80% reduction in TB  
53 notification rates [4].

54 Consequently, it is anticipated that a huge number of cases will remain undiagnosed, and  
55 untreated, further fueling TB transmission rates among household contacts. A report suggests  
56 that India will need to manage 232,665 excess TB cases for every month of lockdown, and  
57 71,290 excess TB deaths which is significantly higher compared to excess cases predicted for  
58 other high burden countries such as Kenya (3,980) and Ukraine (1,058) [4]. In terms of multidrug  
59 resistant TB (MDR-TB), and considering an incidence of 5% (out of overall reported TB  
60 cases), India will see an excess 11,663 MDR-TB cases per month during the pandemic. It is  
61 therefore essential that in addition to the restoration of normal TB services, supplementary  
62 measures are instigated, with a focus on reducing the prevalent pool of TB in endemic settings.  
63 Such measures may involve a combination of intensive community engagement, maintaining  
64 awareness of the importance of TB services and enhanced active case-finding efforts, including  
65 rapid scale-up of contact tracing where possible to compensate for missed diagnoses imposed  
66 by the lockdown. Additional innovative approaches such as the use of digital technology and  
67 other tools will be encouraged.

68 In terms of social distancing, clearly challenges lie ahead. TB patients often live in crowded  
69 conditions with poor hygiene, which increases their risk of getting COVID-19. It is thus vital  
70 that TB patients can be isolated to minimize the occurrence of severe co-infections in view of  
71 their depressed immunity & hospitalizations. Such enhanced social distancing measures should  
72 be targeted more clearly towards those with MDR-TB. While current available literature on  
73 COVID-19 infection in TB patients remains limited, it is anticipated that co-infections will  
74 lead to poorer treatment outcomes. Concerningly, recent reports suggest that influenzal co-

75 infection may be capable of exploiting and altering innate immune defense mechanisms,  
76 thereby exacerbating pulmonary TB and promoting the likelihood of developing secondary  
77 bacterial infections [5].

78 Thus, a robust integrated effort from policy makers, state and national government and NGOs  
79 is now needed to reduce the burden of tuberculosis through urgently maintaining continuity of  
80 essential services, accelerated surveillance of vulnerable populations and asymptomatic  
81 contacts to identify high-risk groups, and through gathering high quality molecular  
82 epidemiologic research.

83

#### 84 **Authors Contribution**

85 **Conceptualization:** Husain AA, Monaghan TM, Kashyap RS. **Writing original draft:**  
86 Husain AA. **Writing – Review & Editing:** Monaghan TM, Kashyap RS

87

#### 88 **Conflict of Interest**

89 TM is a consultant advisor for CHAIN Biotechnology.

90

#### 91 **Funding**

92 No external funding was received for the present work

93

#### 94 **Acknowledgement**

95 Authors acknowledge support of Dr. Amit Nayak and Mr. Rupam Nashine in data collection  
96 for manuscript.

97

98

99

100 **References**

- 101 1. World Health Organization. Global TB report 2019. WHO/CDS/TB/2019.15  
102 [Internet]. Geneva: Available from: [https://www.who.int/publications/i/item/global-](https://www.who.int/publications/i/item/global-tuberculosis-report-2019)  
103 tuberculosis-report-2019 [Accessed 20th May 2020]
- 104 2. Kashyap RS, Nayak AR, Gaherwar HM, Husain AA, Shekhawat SD, Jain RK et al.  
105 Latent TB infection diagnosis in population exposed to TB subjects in close and poor  
106 ventilated high TB endemic zone in India. *PLoS One* 2014; 9:e89524.
- 107 3. Worldometer: Covid-19 Coronavirus Pandemic; Available at  
108 <https://www.worldometers.info/coronavirus/> [Accessed 30<sup>th</sup> June 2020]
- 109 4. Stop TB partnership. The potential impact of the covid-19 response on tuberculosis in  
110 high-burden countries: a modelling analysis. Available at  
111 [http://www.stoptb.org/assets/documents/news/Modeling%20Report\\_1%20May%202020](http://www.stoptb.org/assets/documents/news/Modeling%20Report_1%20May%202020_20_FINAL.pdf)  
112 [20\\_FINAL.pdf](http://www.stoptb.org/assets/documents/news/Modeling%20Report_1%20May%202020_20_FINAL.pdf) [ Accessed 23 May 2020]
- 113 5. Walaza S, Cohen C, Tempia S, et al. Influenza and tuberculosis co-infection: A  
114 systematic review. *Influenza Other Respir Viruses* 2020;14:77-91.  
115